Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3536-3544

  Angele, S ^a   Treilleux, I ^a   Taniere, P ^a   Martel Planche, G ^a   Vuillaume, M ^a   Bailly, C ^a   Bremond, A ^a   Montesano, R ^a   Hall, J ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ALLELIC IMBALANCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION, MISSENSE; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0033822948     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Inherited breast cancer: An emerging picture
2. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
3. Cancer risks in A-T heterozygotes
4. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
5. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: Haplotype study in French AT families
6. A, Loss of heterozygosity in sporadic human breast carcinoma: A region between 11q22 and 11q23.3
7. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancer
8. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions
9. Loss of heterozygosity at 11q23.1 in breast carcinomas: Indication for involvement of a gene distal and close to ATM
10. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma
11. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer
12. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
13. High incidence of cancer in a family segregating a mutation of the ATM gene: Possible role of ATM heterozygosity in cancer
14. The ATM gene and breast cancer: Is it really a risk factor?
15. Up-regulation of ATM in sclerosing adenosis of the breast
16. ATM protein synthesis patterns in sporadic breast cancer
17. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas
18. p53 Mutations in breast cancer: Incidence and relations to tumor aggressiveness and evolution of the disease
19. p53 and human cancer: The first ten thousand mutations
20. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
21. The role of ATM in DNA damage responses and cancer
22. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
23. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
24. Regulation of p53 response to DNA damage
25. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
26. Enhanced phosphorylation of p53 by ATM in response to DNA damage
27. NS22: A highly polymorphic complex microsatellite marker within the ATM gene
28. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors
29. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
30. Inactivation of the p53 protein in cell lines derived from human esophageal cancers
31. Predominance of null mutations in ataxia-telangiectasia
32. Restriction endonuclease fingerprinting (REF): A sensitive method for screening mutations in long, contiguous segments of DNA
33. A single ataxia-telangiectasia gene with a product similar to PI 3-kinase
34. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms
35. ATM binds to β-adaptin in cytoplasmic vesicles
36. Localization of a portion of extranuclear ATM to peroxisomes
37. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: Identification of a new region at 11q23.3
38. Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region
39. A human gene encoding a putative DEAD-box RNA helicase at 11q22-23
40. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: Association with poor survival
41. The Breast Cancer Somatic Genetics Consortium: European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: Relation to clinical variables
42. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23
43. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer
44. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
45. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region
46. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
47. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors
48. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers
49. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene
50. Methylation of the BRCA1 gene in sporadic breast cancer
51. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics
52. Ataxia-telangiectasia and T-cell leukemias: No evidence for somatic ATM mutations in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL
53. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patient
54. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
55. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
56. The role of the ataxia-telangiectasia gene in the p53, WAF1/CIP1(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation
57. Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients
58. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
59. Signaling to p53: Breaking the MDM2-p53 circuit
60. Mdm2: The ups and downs
61. Functions of the MDM2 oncoprotein
62. Insights into the functions of BRCA 1 and BRCA2
63. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks
64. Substrate specificities and identification of putative substrates of ATM kinase family members